PARIS (January 6, 2017) – International law firm McDermott Will & Emery advised French-based Servier, an international pharmaceutical company, in its license option agreement with OSE Immunotherapeutics on the exclusive worldwide rights for the development and commercialization of the Effi-7 product. Effi-7 is a monoclonal immunomodulatory antibody.
OSE Immunotherapeutics is eligible to receive up to €272 million upon the exercise of a two-steps option license. These steps will enable the development of Effi-7 up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease.
The McDermott team advising on the transaction comprised of Paris-based partners Emmanuelle Trombe and Anthony Paronneau, along with associates Raphaëlle Monjou and Louise Aberg.
McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.
About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.